Multinationals Start 2021 Empty Handed In China National Reimbursement Race
But Broader IO Indications An Advantage?
China's latest round of reimbursement decisions show multinationals including AstraZeneca, BMS and Roche won’t be receiving national coverage for their latest immuno-oncology drugs any time soon.
You may also be interested in...
Novartis China Drive Paying Off, Sales Soar On Reimbursement Inclusion
Sales of the Swiss drug maker's major plaque psoriasis treatment Cosentyx in China quadrupled in the second quarter, despite its price being slashed by more than 60%.
China’s Internet Hospitals And New Commercial Models For Pharma
Pharma is leveraging new commercial models in China as part of strategies to offset centralized procurements-induced market share losses and also for new launches, the co- founder of Indegene, a healthtech solutions provider, tells Scrip. He also shares insights on how companies in Japan are shifting digital gears amid COVID-19.
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.